Hug E B, Loredo L N, Slater J D, DeVries A, Grove R I, Schaefer R A, Rosenberg A E, Slater J M
Department of Radiation Medicine, Loma Linda University Medical Center, California 92354, USA.
J Neurosurg. 1999 Sep;91(3):432-9. doi: 10.3171/jns.1999.91.3.0432.
Local tumor control, patient survival, and treatment failure outcomes were analyzed to assess treatment efficacy in 58 patients in whom fractionated proton radiation therapy (RT) was administered for skull base chordomas and chondrosarcomas.
Between March 1992 and January 1998, a total of 58 patients who could be evaluated were treated for skull base tumors, 33 for chordoma and 25 for chondrosarcoma. Following various surgical procedures, residual tumor was detected in 91% of patients; 59% demonstrated brainstem involvement. Target dosages ranged from 64.8 and 79.2 (mean 70.7) Co Gy equivalent. The range of follow up was 7 to 75 months (mean 33 months). In 10 patients (17%) the treatment failed locally, resulting in local control rates of 92% (23 of 25 patients) for chondrosarcomas and 76% (25 of 33 patients) for chordomas. Tumor volume and brainstem involvement influenced control rates. All tumors with volumes of 25 ml or less remained locally controlled, compared with 56% of tumors larger than 25 ml (p = 0.02); 94% of patients without brainstem involvement did not experience recurrence; in patients with brainstem involvement (and dose reduction because of brainstem tolerance constraints) the authors achieved a tumor control rate of 53% (p = 0.04). Three patients died of their disease, and one died of intercurrent disease. Actuarial 5-year survival rates were 100% for patients with chondrosarcoma and 79% for patients with chordoma. Grade 3 and 4 late toxicities were observed in four patients (7%) and were symptomatic in three (5%).
High-dose proton RT offers excellent chances of lasting tumor control and survival, with acceptable risks. In this series all small- and medium-sized tumors with no demonstrable brainstem involvement have been controlled; all such patients are alive. Surgical debulking enhanced delivery of full tumoricidal doses, but even patients with large tumors and disease abutting crucial normal structures benefited.
分析局部肿瘤控制、患者生存率及治疗失败结局,以评估58例接受分次质子放射治疗(RT)的颅底脊索瘤和软骨肉瘤患者的治疗效果。
1992年3月至1998年1月期间,共58例可评估的患者接受了颅底肿瘤治疗,其中33例为脊索瘤,25例为软骨肉瘤。经过各种手术操作后,91%的患者检测到残留肿瘤;59%的患者显示脑干受累。靶剂量范围为64.8至79.2(平均70.7)钴 Gy 当量。随访时间为7至75个月(平均33个月)。10例患者(17%)出现局部治疗失败,软骨肉瘤的局部控制率为92%(25例患者中的23例),脊索瘤为76%(33例患者中的25例)。肿瘤体积和脑干受累影响控制率。所有体积在25 ml或以下的肿瘤均保持局部控制,而体积大于25 ml的肿瘤为56%(p = 0.02);94%无脑干受累的患者未出现复发;在有脑干受累(且因脑干耐受性限制而降低剂量)的患者中,作者实现了53%的肿瘤控制率(p = 0.04)。3例患者死于疾病,1例死于并发疾病。软骨肉瘤患者的5年精算生存率为100%,脊索瘤患者为79%。4例患者(7%)观察到3级和4级晚期毒性,其中3例(5%)有症状。
高剂量质子RT提供了持久肿瘤控制和生存的良好机会,且风险可接受。在本系列中,所有无明显脑干受累的中小型肿瘤均得到控制;所有此类患者均存活。手术减瘤增强了全杀瘤剂量的递送,但即使是患有大肿瘤且疾病紧邻关键正常结构的患者也从中受益。